Rossari Biotech Limited has disclosed that its material subsidiary, Unitop Chemicals Private Limited, has approved the sale of office premises in Mumbai for Rs 10 crores. The transaction was approved by the subsidiary's Board of Directors on April 03, 2026, marking a significant asset divestment for the group.

Transaction Details

The subsidiary has agreed to sell its office premises located at Saki Naka, Mumbai at a consideration of approximately Rs 10 crores (Rupees Ten Crore only). The proposed transaction is expected to reach completion by the end of Q2 FY27, providing a clear timeline for the asset disposal.

Operational Impact Assessment

The company has provided assurance regarding the transaction's impact on business operations. As no business operations are currently conducted from the premises proposed to be sold by the subsidiary, the sale will not have any impact on either the company's or subsidiary's business operations. This strategic decision appears to be focused on asset optimization rather than operational restructuring.

Regulatory Compliance

The disclosure has been made pursuant to Regulation 30(9) read with Schedule III of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company has confirmed that the sale of the premises does not constitute the sale of an undertaking within the meaning of Section 180(1)(a) of the Companies Act, 2013.

Additional details required under Regulation 30 of the Listing Regulations, as per SEBI Master Circular no. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026, will be provided upon execution of the agreement. This ensures full regulatory compliance throughout the transaction process.

Corporate Structure Context

Unitop Chemicals Private Limited operates as a material subsidiary of Rossari Biotech Limited, making this transaction significant enough to warrant disclosure under regulatory requirements. The parent company maintains its registered office at Rossari House, Golden Oak, LBS Marg, Surya Nagar, Vikhroli (West), Mumbai, with manufacturing facilities in Silvassa and Gujarat.

Rossari Biotech Limited has submitted its quarterly compliance certificate to stock exchanges for the quarter ended March 31, 2026, fulfilling regulatory requirements under SEBI Depositories Regulations.

Regulatory Filing Details

The company filed the compliance certificate on April 3, 2026, addressing both BSE Limited and National Stock Exchange of India Limited. The submission was made under Regulation 74(5) of Securities and Exchange Board of India (Depositories and Participants) Regulations, 2018.

Registrar Confirmation

MUFG Intime India Private Limited, serving as the company's Registrar and Share Transfer Agent, provided confirmation regarding the dematerialisation process. The registrar confirmed that all securities received from depository participants during the quarter were processed according to regulatory requirements.

Key confirmations from the registrar include:

• Securities received for dematerialisation were confirmed to depositories within prescribed timelines
• Security certificates were mutilated and cancelled after due verification
• Names of depositories were substituted in the register of members as registered owners
• All securities are listed on stock exchanges where earlier issued securities are listed

Notable Quarter Activity

The registrar specifically noted that no remat requests were received for processing during the quarter ended March 31, 2026. This indicates no requests for conversion of shares from electronic to physical form were made during this period.

Company Information

Rossari Biotech Limited operates as an ISO 9001:2015 & 14001:2015 certified company with CIN L24100MH2009PLC194818. The company maintains its registered office in Mumbai and operates manufacturing facilities in Silvassa and Gujarat.

The compliance certificate filing demonstrates the company's adherence to regulatory requirements for share dematerialisation processes and maintains transparency with stock exchange authorities and shareholders.